Bioenergetic medicine
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Here we discuss a specific therapeutic strategy we call ‘bioenergetic medicine’. Bioenergetic medicine refers to the manipulation of bioenergetic fluxes to positively affect health. Bioenergetic medicine approaches rely heavily on the law of mass action, and impact systems that monitor and respond to the manipulated flux. Since classically defined energy metabolism pathways intersect and intertwine, targeting one flux also tends to change other fluxes, which complicates treatment design. Such indirect effects, fortunately, are to some extent predictable, and from a therapeutic perspective may also be desirable. Bioenergetic medicine‐based interventions already exist for some diseases, and because bioenergetic medicine interventions are presently feasible, new approaches to treat certain conditions, including some neurodegenerative conditions and cancers, are beginning to transition from the laboratory to the clinic. Linked Articles: This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 2×
“…inhibition or other means could potentially enhance, may be leveraged to remove defective mitochondria (Bergamini et al., 2003; Zemke et al., 2007; Harrison et al., 2009; Hepple, 2009; Banerjee et al., 2010; Jung et al., 2010; Kapahi et al., 2010; Rabinowitz and White, 2010; Sudarsanam and…”
BackgroundHypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Oxidative damage and mitochondrial decay in aging.
Shigenaga, M. K., Hagen, T. M., & Ames, B. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10771 · Cited by 2,055 · cited 1×
“When both are present, cause and consequence relationships require careful consideration, as oxidative stress impairs respiratory chain function and respiratory chain function increases oxidative stress (Shigenaga et al., 1994; Brown, 1999; Riobo et al., 2001; Swerdlow, 2012a).”
BackgroundMitochondria: Dynamic Organelles in Disease, Aging, and Development
Chan, D. C. (2006) · Cell · doi:10.1016/j.cell.2006.06.010 · Cited by 1,987
Rabinowitz, J. D., & White, E. (2010) · Science · doi:10.1126/science.1193497 · Cited by 1,982
Tripartite synapses: astrocytes process and control synaptic information
Perea, G., Navarrete, M., & Araque, A. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.05.001 · Cited by 1,820 · cited 1×
“This bioenergetic relationship likely plays an especially important role during action potential-induced synaptic activity, and defines a ‘tripartite synapse’ that functionally differs from the traditional bipartite synapse (Pellerin and Magistretti, 2004; Perea et al., 2009; Faissner et al., 2010).”
BackgroundAstrocyte-Neuron Lactate Transport Is Required for Long-Term Memory Formation
Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., & Alberini, C. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.018 · Cited by 1,711
Transcriptional paradigms in mammalian mitochondrial biogenesis and function
Scarpulla, R. C. (2008) · Physiological Reviews · doi:10.1152/physrev.00025.2007 · Cited by 1,666
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“The overall picture is somewhat murky, and some findings may be tissue-specific, but data argue that at least for a period of time during adulthood, some tissues increase their mitochondrial mass (Barrientos et al., 1997a; 1997b; Hirai et al., 2001; Manczak et al., 2005).”
BackgroundImpaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease
Wang, X., Su, B., Lee, H.-G., Li, X., Perry, G., Smith, M. A., & Zhu, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1357-09.2009 · Cited by 1,224
Schulz, T. J., Zarse, K., Voigt, A., Urban, N., Birringer, M., & Ristow, M. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.08.011 · Cited by 1,209 · cited 1×
“In support of this, antioxidants appear to minimize exercise-induced mitochondrial biogenesis in human subjects, as well as glycolysis inhibition-induced mitochondrial biogenesis in Caenorhabditis elegans (Schulz et al., 2007; Ristow et al., 2009).”
BackgroundSelective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009093200 · Cited by 1,091
The role of mitochondria in aging
Bratic, A., & Larsson, N.-G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64125 · Cited by 1,087 · cited 1×
“1856 British Journal of Pharmacology (2014) 171 1854–1869 advancing age (Navarro and Boveris, 2007; Boveris and Navarro, 2008; Bratic and Larsson, 2013).”
BackgroundEarly mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Cárdenas, C., Miller, R. A., Smith, I., Bui, T., Molgó, J., Müller, M., Vais, H., Cheung, K.-H., Yang, J., Parker, I., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.007 · Cited by 1,026 · cited 1×
“Mitochondria absorb some of this calcium, and the resulting acute depolarization increases mitochondrial oxygen consumption (Cardenas et al., 2010).”
BackgroundCui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 2×
“A phase II placebo-controlled trial of CoQ in PD patients initially suggested those receiving it declined less over time than those receiving placebo (Shults et al., 2002), but this finding remains to be confirmed in a definitive trial (Storch et al.”
BackgroundResultMorino, K., Petersen, K. F., & Shulman, G. I. (2006) · Diabetes · doi:10.2337/db06-s002 · Cited by 853 · cited 2×
“Mitochondrial function also likely influences insulin resistance, with mitochondrially generated oxidative stress perhaps mediating this phenomenon (Morino et al., 2006; Rains and Jain, 2011).”
BackgroundA “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758 · cited 1×
“A ‘mitochondrial cascade hypothesis’ assumes this latter possibility (Swerdlow and Khan, 2004; Swerdlow and Khan, 2009; Swerdlow et al., 2010).”
BackgroundSelf-citationMonocarboxylate transporters in the central nervous system: distribution, regulation and function
Pierre, K., & Pellerin, L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03168.x · Cited by 744
Nitric oxide and mitochondrial respiration
Brown, G. C. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00025-0 · Cited by 702
Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects
BONNEFONT, J. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.004 · Cited by 637 · cited 1×
“In carnitine palmitoyl transferase deficiency, the abnormal protein resides within mitochondria and directly effects substrate delivery to the fatty acid β-oxidation pathway (Bonnefont et al., 2004).”
BackgroundCytochrome oxidase deficiency in Alzheimer’s disease
Parker, W. D., Filley, C. M., & Parks, J. K. (1990) · Neurology · doi:10.1212/wnl.40.8.1302 · Cited by 598 · cited 1×
“Cytochrome oxidase (COX), pyruvate dehydrogenase complex (PDHC) and α-ketoglutarate dehydrogenase complex activities tend to run lower in AD subjects than they do in agematched control subjects (Parker et al., 1990; Gibson et al., 2010; Swerdlow, 2012b).”
BackgroundThe Alzheimer’s Disease Mitochondrial Cascade Hypothesis
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100339 · Cited by 562 · cited 1×
“A ‘mitochondrial cascade hypothesis’ assumes this latter possibility (Swerdlow and Khan, 2004; Swerdlow and Khan, 2009; Swerdlow et al., 2010).”
BackgroundFeron, O. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.025 · Cited by 559 · cited 2×
“The Warburg effect, in which cells boost glycolysis rates and de-emphasize aerobic ATP production, occurs in cancer (Feron, 2009; Vander Heiden et al., 2009).”
BackgroundThe role of mitochondria in the pathogenesis of type 2 diabetes
Patti, M.-E., & Corvera, S. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0027 · Cited by 551
Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging
Kalpouzos, G., Chételat, G., Baron, J.-C., Landeau, B., Mevel, K., Godeau, C., Barré, L., Constans, J.-M., Viader, F., Eustache, F., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.019 · Cited by 392 · cited 1×
“In the brain, this includes decreasing glucose utilization, which suggests reduced glycolysis flux (De Santi et al., 1995; Willis et al., 2002; Kalpouzos et al., 2009; Chetelat et al., 2013; Marano et al., 2013).”
BackgroundShults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
Brain aging, Alzheimer's disease, and mitochondria
Swerdlow, R. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.012 · Cited by 306 · cited 7×
“If this truly happens in the face of declining electron transport chain (ETC) Vmax activities, such changes could represent a compensatory up-regulation (Swerdlow, 2011a).”
BackgroundInfluentialSelf-citationWu, Z., Huang, X., Feng, Y., Handschin, C., Feng, Y., Gullicksen, P. S., Bare, O., Labow, M., Spiegelman, B., & Stevenson, S. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606714103 · Cited by 291
RIOBÓ, N. A., CLEMENTI, E., MELANI, M., BOVERIS, A., CADENAS, E., MONCADA, S., & PODEROSO, J. J. (2001) · Biochemical Journal · doi:10.1042/bj3590139 · Cited by 278 · cited 1×
“When both are present, cause and consequence relationships require careful consideration, as oxidative stress impairs respiratory chain function and respiratory chain function increases oxidative stress (Shigenaga et al., 1994; Brown, 1999; Riobo et al., 2001; Swerdlow, 2012a).”
BackgroundCybrids in Alzheimer's disease: a cellular model of the disease?
Swerdlow, R. H., Parks, J. K., Cassarino, D. S., Maguire, D. J., Maguire, R. S., Bennett, J. P., Davis, R. E., & Parker, W. D. (1997) · Neurology · doi:10.1212/wnl.49.4.918 · Cited by 272
Self-citationBrain mitochondrial dysfunction in aging
Boveris, A., & Navarro, A. (2008) · IUBMB Life · doi:10.1002/iub.46 · Cited by 235
Faissner, A., Pyka, M., Geissler, M., Sobik, T., Frischknecht, R., Gundelfinger, E. D., & Seidenbecher, C. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.01.001 · Cited by 207 · cited 1×
“This bioenergetic relationship likely plays an especially important role during action potential-induced synaptic activity, and defines a ‘tripartite synapse’ that functionally differs from the traditional bipartite synapse (Pellerin and Magistretti, 2004; Perea et al., 2009; Faissner et al., 2010).”
BackgroundThe Alzheimer's disease mitochondrial cascade hypothesis: an update
Swerdlow, R. H., & Khan, S. M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.01.011 · Cited by 206
Self-citationStorch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205 · cited 2×
“A phase II placebo-controlled trial of CoQ in PD patients initially suggested those receiving it declined less over time than those receiving placebo (Shults et al., 2002), but this finding remains to be confirmed in a definitive trial (Storch et al., 2007).”
BackgroundAdaptation of skeletal muscle to endurance exercise
HOLLOSZY, J. O. (1975) · Medicine and Science in Sports and Exercise · doi:10.1249/00005768-197500730-00013 · Cited by 186
Cookson, M. R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009415 · Cited by 170 · cited 1×
“Fifth, in many cases, the mutated proteins that cause Mendelian PD affect mitochondrial physiology (Tan and Skipper, 2007; Cookson, 2012).”
BackgroundAlmeida, A., Bolaños, J. P., & Moncada, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913668107 · Cited by 166 · cited 1×
“We do not fully understand the Warburg effect’s relevance to carcinogenesis, or how it originates, although several potential explanations exist (Ferguson and Rathmell, 2008; Feron, 2009; Vander Heiden et al., 2009; Almeida et al., 2010).”
BackgroundGutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162 · cited 1×
“Several placebo-controlled trials have argued idebenone may marginally slow cognitive decline in AD subjects, although neither idebenone nor CoQ is currently approved for the treatment of AD (Weyer et al., 1997; Gutzmann and Hadler, 1998; Thal et al., 2003).”
BackgroundIdebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156
Age, sex and laterality effects on cerebral glucose metabolism in healthy adults
Willis, M. W., Ketter, T. A., Kimbrell, T. A., George, M. S., Herscovitch, P., Danielson, A. L., Benson, B. E., & Post, R. M. (2002) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00126-3 · Cited by 150
Barrientos, A., Casademont, J., Cardellach, F., Estivill, X., Urbano-Marquez, A., & Nunes, V. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00278-7 · Cited by 149 · cited 2×
“The overall picture is somewhat murky, and some findings may be tissue-specific, but data argue that at least for a period of time during adulthood, some tissues increase their mitochondrial mass (Barrientos et al., 1997a; 1997b; Hirai et al., 2001; Manczak et al., 2005).”
BackgroundCytochrome C Oxidase in Alzheimer's Disease Brain: Purification and Characterization
Parker, W. D., & Parks, J. K. (1995) · Neurology · doi:10.1212/wnl.45.3.482 · Cited by 142
Silva, D. F., Selfridge, J. E., Lu, J., E, L., Roy, N., Hutfles, L., Burns, J. M., Michaelis, E. K., Yan, S., Cardoso, S. M., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt247 · Cited by 133 · cited 4×
“…the transfer of AD subject platelet mitochondria to neuroblastoma and teratocarcinoma cells previously depleted of endogenous mtDNA show low COX activity, a finding that persists over months of continuous culture (Swerdlow et al., 1997; Cardoso et al., 2004; Swerdlow, 2012b; Silva et al., 2013).”
BackgroundInfluentialSelf-citationA Controlled Study of 2 Doses of Idebenone in the Treatment of Alzheimer’s Disease
Weyer, G., Babej-Dölle, R. M., Hadler, D., Hofmann, S., & Herrmann, W. M. (2008) · Neuropsychobiology · doi:10.1159/000119366 · Cited by 120 · cited 1×
“Several placebo-controlled trials have argued idebenone may marginally slow cognitive decline in AD subjects, although neither idebenone nor CoQ is currently approved for the treatment of AD (Weyer et al., 1997; Gutzmann and Hadler, 1998; Thal et al., 2003).”
BackgroundMitochondrial signaling, TOR, and life span
Schieke, S. M., & Finkel, T. (2006) · Biological Chemistry · doi:10.1515/bc.2006.170 · Cited by 106 · cited 1×
“Minimizing the production or impact of mitochondriagenerated free radicals, though, could also theoretically dampen compensatory stress responses, with potentially British Journal of Pharmacology (2014) 171 1854–1869 1859 adverse consequences (Finkel, 2003; Schieke and Finkel, 2006).”
BackgroundChételat, G., Landeau, B., Salmon, E., Yakushev, I., Bahri, M. A., Mézenge, F., Perrotin, A., Bastin, C., Manrique, A., Scheurich, A., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.03.009 · Cited by 92 · cited 1×
“In the brain, this includes decreasing glucose utilization, which suggests reduced glycolysis flux (De Santi et al., 1995; Willis et al., 2002; Kalpouzos et al., 2009; Chetelat et al., 2013; Marano et al., 2013).”
BackgroundTreating neurodegeneration by modifying mitochondria: potential solutions to a “complex” problem
Swerdlow, R. H. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1676 · Cited by 81
Self-citationDe Santi, S., de Leon, M. J., Convit, A., Tarshish, C., Rusinek, H., Tsui, W. H., Sinaiko, E., Wang, G.-J., Bartlet, E., & Volkow, N. (1995) · Psychiatric Quarterly · doi:10.1007/bf02238755 · Cited by 74
Mitochondrial medicine and the neurodegenerative mitochondriopathies
Swerdlow, R. H. (2009) · Pharmaceuticals · doi:10.3390/ph2030150 · Cited by 43 · cited 6×
“Mitochondrial dysfunction is frequently seen, and diseases in which mitochondria appear to play particularly upstream roles are sometimes considered ‘mitochondriopathies’ (Swerdlow, 2009a; Swerdlow, 2009b).”
BackgroundInfluentialH. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35
Longitudinal studies of cerebral glucose metabolism in late-life depression and normal aging
Marano, C. M., Workman, C. I., Kramer, E., Hermann, C. R., Ma, Y., Dhawan, V., Chaly, T., Eidelberg, D., & Smith, G. S. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3840 · Cited by 24 · cited 1×
“In the brain, this includes decreasing glucose utilization, which suggests reduced glycolysis flux (De Santi et al., 1995; Willis et al., 2002; Kalpouzos et al., 2009; Chetelat et al., 2013; Marano et al., 2013).”
Background
Cited by
Mitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850
“Pharmacologic manipulations that enhance aerobic or other aspects of mitochondrial function, or overall cell bioenergetics, could prove beneficial [148].”
BackgroundSelf-citationThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
Self-citationPerez Ortiz, J. M., & Swerdlow, R. H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14585 · Cited by 426
Self-citationFeasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease
Taylor, M. K., Sullivan, D. K., Mahnken, J. D., Burns, J. M., & Swerdlow, R. H. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.11.002 · Cited by 272
Self-citationMitochondria, Cybrids, Aging, and Alzheimer's Disease
Swerdlow, R. H., Koppel, S., Weidling, I., Hayley, C., Ji, Y., & Wilkins, H. M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.12.017 · Cited by 106
Self-citation
Metadata
- Authors
- Swerdlow, R. H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-03-28
- Volume
- 171
- Issue
- 8
- Pages
- 1854-1869
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2328728848
- Cited by
- 49
- References
- 54
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.